<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579137</url>
  </required_header>
  <id_info>
    <org_study_id>21123-MASCI</org_study_id>
    <nct_id>NCT00579137</nct_id>
    <nct_alias>NCT00609258</nct_alias>
  </id_info>
  <brief_title>Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders</brief_title>
  <acronym>MASCI</acronym>
  <official_title>CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to discover whether children with severe combined immunodeficiency disease
      (SCID) or other primary immunodeficiency disorder (PID) for which no satisfactory treatment
      other than stem cell transplantation (SCT) exists can be safely and effectively transplanted
      from HLA mismatched (up to one haplotype) related donors or unrelated matched or mismatched
      (up to one antigen) donors, when leukocytolytic monoclonal antibodies (MAb) and Fludarabine
      are the sole conditioning agents. Three monoclonal antibodies will be used in combination.
      Two of them are rat IgG1 (immunoglobulin G1) antibodies directed against two contiguous
      epitopes on the CD45 (common leucocyte) antigen. They have been safely administered as part
      of the conditioning regimen for 12 patients receiving allografts (HLA matched and mismatched)
      at this center. They produce a transient depletion of &gt;90% circulating leucocytes. The third
      MAb is Campath 1H, a humanized rat anti-CD52 MAb. Campath 1H, Alemtuzumab, has been licensed
      to treat B-cell chronic lymphocytic leukemia (B-CLL) and more recently has been safely given
      at this and other centers as part of a sub-ablative conditioning regimen to patients with
      malignant disease. Because these MAb produce both profound immunosuppression and significant,
      though transient, myelodestruction we believe they may be useful as the sole conditioning
      regimen in patients with SCID, in whom the use of conventional chemotherapeutic agents for
      conditioning may produce or aggravate unacceptable and even lethal short term toxicity. We
      anticipate MAb mediated subablative conditioning will permit engraftment in a high percentage
      of these patients with little or no immediate or long term toxicity. Campath IH persists in
      vivo for several days after administration and so will be present over the transplant period
      to deplete donor T cells as partial GvHD prophylaxis. Additional Graft versus Host Disease
      (GvHD) prophylaxis may be provided by administration of FK506.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Donor Stem Cell Processing for Mismatched Donors: Harvested peripheral blood stem cells will
      be enriched for CD34 cells using the CliniMACS CD34 Reagent system, according to Center for
      Cell and Gene Therapy (CAGT) SOPs.

      Stem Cell Transplant Conditioning

      Campath-1H will be given as 3 daily intravenous infusions and will be followed by Anti-CD45
      which will be given as four daily intravenous infusions that will be completed two days prior
      to stem cell infusion. Diphenydramine will be administered i.v. q4h during the period of the
      course of the Campath and Anti-CD45 infusions.

      Day

      8 Campath 1H as per CAGT SOP Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2

      7 Campath 1H as per CAGT SOP Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2

      6 Campath 1H as per CAGT SOP Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2

      5 YTH 24/54 400ug/kg over 6 hr Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2

      4 YTH 24/54 400ug/kg over 6 hr Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2

      3 YTH 24/54 400ug/kg over 6 hr

      2 YTH 24/54 400ug/kg over 6 hr

      1 rest

      0 Stem Cell Infusion

      Campath 1H Infusion- Campath dose is weight based: for patients less than 15 killograms (kg)
      administer Campath 3 mg; for patients &gt;15 kg to 30 kg administer Campath 5 mg; for patients &gt;
      30 kg administer Campath 10 mg. Campath will be dosed and administered as per CAGT SOP.

      Anti-CD45- Infusion Anti-CD45 infusion will be administered according to CAGT SOPs. 3 ml of
      heparinized blood will be drawn 48 hr post Anti-CD45 to evaluate for free Anti-CD45 levels in
      the plasma. This estimation will be used to determine whether treatment with irradiated
      leukocytes is required before the bone marrow is infused.

      GVHD Prophylaxis- GVHD prophylaxis will be achieved through positive selection for CD34
      resulting in &gt; 3 log T cell depletion. Previous reports have indicated that there is a low
      frequency of severe (Grade II/IV) GVHD after haploidentical transplants if recipients receive
      stem cell populations containing &lt;5 x 10 CD3 positive T cells. We hope to achieve such levels
      with our CD34 enrichment protocol. However, pharmacologic prophylaxis will be added if the
      CD34 selected product contains more than 5 x 10 CD3+ve T cells/kg recipient weight. In
      addition, Campath 1H persists in the recipient circulation through the immediate transplant
      period and will contribute anti-GVHD activity, in vivo. Patients who develop acute or chronic
      GVHD will be managed according to CAGT SOPs.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Donor Engraftment</measure>
    <time_frame>100 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Alive at 1 Year</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade III or IV Toxicity</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade III to IV Acute GVHD</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Severe Combined Immunodeficiency Disease</condition>
  <condition>Severe Primary Immunodeficiency Disorder</condition>
  <condition>Undefined T Cell Deficiency Disorder</condition>
  <condition>Wiskott-Aldrick Syndrome</condition>
  <arm_group>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Campath -1H</intervention_name>
    <description>Given intravenous on Days -8,-7, and -6
Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients &gt;15 kg to 30 kg the dose 5 mg; for patients &gt; 30 kg the dose is 10 mg</description>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given intravenous on Days -8,-7,-6,-5, and -4
Dose is 30 mg/m2</description>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD45</intervention_name>
    <description>Given intravenous over 6 hours on Days -5,-4,-3, and -2
Dose is 400 microgram/kg</description>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell infusion</intervention_name>
    <description>stem cells are infused on day 0</description>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients with a diagnosis of: Severe combined immunodeficiency disease

        This includes patients whose SCID is characterized by gene specific mutations as well as
        patients with clinically severe combined immunodeficiency without a defined genetic cause
        in which the diagnosis will be determined by a combination of clinical course with
        lymphocyte quantification and function assays.

        OR

        Severe primary immunodeficiency disorder, including undefined T cell deficiency disorder,
        Wiskott-Aldrich syndrome, and other severe immunodeficiencies for which satisfactory
        conventional therapy does not exist.

          -  Availability of an HLA mismatched (up to one haplotype) family member or an HLA
             matched or mismatched (up to one antigen) unrelated donor.

          -  Creatinine &lt; 2.5 x normal for age.

          -  Life expectancy greater than 6 weeks

          -  Lansky/Karnofsky greater than or equal to 70%

        Exclusion Criteria:

          -  Patients with an HLA matched related donor

          -  Patients with symptomatic cardiac disease, or evidence of significant cardiac disease
             by echocardiogram (i.e., shortening fraction less than 25%)

          -  Patients with known allergy to rat serum products

          -  Patients with a severe infection that on evaluation by the Principal Investigator
             precludes ablative chemotherapy or successful transplantation

          -  HIV positive

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Krance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malcolm Brenner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>March 30, 2013</results_first_submitted>
  <results_first_submitted_qc>June 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2013</results_first_posted>
  <last_update_submitted>June 28, 2013</last_update_submitted>
  <last_update_submitted_qc>June 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Robert Krance</investigator_full_name>
    <investigator_title>Professor Pediatrics Hematology Oncology Center for Cell and Gene Therapy</investigator_title>
  </responsible_party>
  <keyword>Severe Combined Immunodeficiency Disease</keyword>
  <keyword>Severe Primary Immunodeficiency Disorder</keyword>
  <keyword>Undefined T cell Deficiency Disorder</keyword>
  <keyword>Wiskott-Aldrick Syndrome</keyword>
  <keyword>Allogeneic stem cell transplant</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>monoclonal antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants With SCID or Primary Immunodeficiency Disorder</title>
          <description>Participants received an allogeneic stem cell transplant with the following conditioning:
Day 8 Campath 1H as per CAGT SOP, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2
D7 Campath 1H as per CAGT SOP, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2
D6 Campath 1H as per CAGT SOP, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2
D5 Anti-CD45 MAb 400ug/kg over 6 hr, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2
D4 Anti-CD45 MAb 400ug/kg over 6 hr, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2
D3 Anti-CD45 MAb 400ug/kg over 6 hr
D2 Anti-CD45 MAb 400ug/kg over 6 hr
D1 rest
D0 Stem Cell Infusion
Campath dose is weight based: for patients less than 15 kg administer Campath 3 mg; for patients &gt;15 kg to 30 kg administer Campath 5 mg; for patients &gt; 30 kg administer Campath 10 mg. Campath will be dosed and administered as per CAGT SOP.
Anti-CD45 infusion will be administered according to CAGT SOPs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Group</title>
          <description>only one group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=1 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Donor Engraftment</title>
        <time_frame>100 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Donor Engraftment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Alive at 1 Year</title>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Alive at 1 Year</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade III or IV Toxicity</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade III or IV Toxicity</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade III to IV Acute GVHD</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade III to IV Acute GVHD</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Group</title>
          <description>only one group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) - Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Other: Liver GvHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other: Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other: Livedo reticularis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Krance, MD</name_or_title>
      <organization>Baylor</organization>
      <phone>832-824-4661</phone>
      <email>rkrance@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

